{"classes":[{"categories":[{"measurements":[{"comment":"Due to low number of events, median and upper limit of CI was not estimable.","groupId":"OG000","lowerLimit":"6.74","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"OS was defined as the time from first dose of the study drug until the documented date of death from any cause. OS was analyzed using Kaplan-Meier estimates. Participants who were still alive at the time of data cutoff date were to be censored at the last known alive date or at the data cutoff date, whichever was earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"MEDIAN","populationDescription":"FAS population","reportingStatus":"POSTED","timeFrame":"From first dose up to death (maximum duration: 9.33 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}